NEW MOLLECULES IN MIGRAINE TREATMENT
ADINA ROCEANU1, FLORINA ANTOCHI1*, OVIDIU BAJENARU1,2
1University Emergency Hospital Bucharest, Neurology Department
2“Carol Davila” University of Medicine and Pharmacy Bucharest, Romania
*corresponding author: flrant@yahoo.com
Download Full Article

Abstract:
In the 1990s, serotonin receptor agonist 5-HT1B/1D (the triptans) became available on the market for migraine treatment.
Although the triptans are highly effective in aborting migraine attacks, the vasoconstrictor effect in cerebral and coronary
territory limits their use. In the “post-triptans” era, new molecules, without vasoactive components are about to expand
migraine treatment armamentarium, such as: serotonin 5-HT1F receptor agonists, calcitonin gene related peptide (CGRP)
receptor antagonists (olcegepant, telcagepant) and monoclonal antibodies (mAbs) targeting the CGRP, glutamate receptor
(AMPA/kainate) antagonists, transient receptor potential vanilloid (TRV1) antagonists, nitric oxide (NO) synthesis
inhibitors, prostanoid E4 receptor antagonists.

Top